Eyegate Pharmaceuticals (NASDAQ:EYEG) has been assigned a $3.00 target price by research analysts at HC Wainwright in a research report issued to clients and investors on Sunday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 424.75% from the company’s previous close.

Separately, ValuEngine upgraded shares of Eyegate Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

Eyegate Pharmaceuticals (NASDAQ EYEG) opened at $0.57 on Friday. Eyegate Pharmaceuticals has a twelve month low of $0.49 and a twelve month high of $2.85. The stock has a market cap of $9.87, a price-to-earnings ratio of -0.61 and a beta of 3.37.

An institutional investor recently raised its position in Eyegate Pharmaceuticals stock. Vanguard Group Inc. boosted its holdings in Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) by 0.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 247,319 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,988 shares during the quarter. Vanguard Group Inc. owned about 2.27% of Eyegate Pharmaceuticals worth $339,000 at the end of the most recent quarter. Institutional investors own 10.51% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2018/03/12/eyegate-pharmaceuticals-eyeg-given-a-3-00-price-target-at-hc-wainwright.html.

Eyegate Pharmaceuticals Company Profile

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.